Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2006-03-15 Interim / Quarterly Rep…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Half Yearly Report & Half Year Accounts 28 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'SHAREHOLDER UPDATE MARCH 2006' and contains detailed financial results for the half year ended 31 December 2005, including net loss, cash flow, and cash position. It also discusses strategic reviews, commercial agreements, research and development updates, patent status, and staff changes. The presence of detailed financial data for a half-year period, including revenue and loss figures, indicates this is a comprehensive interim financial report. The document is about 15,000 characters long, which is consistent with a substantive report rather than a brief announcement. The content aligns with an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and includes actual financial statements and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2006-03-15 English
New Trial Commences for Lead Poultry Product 2 pages ?Kb
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement dated March 13, 2006, regarding the commencement of a new trial for Imugene Limited's lead poultry product. It describes the trial design, objectives, and background information about the product and company. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The content is focused on a product development update and trial commencement, which is typical of a Capital/Financing Update or a general company announcement. However, since it is about a trial commencement and product development progress rather than fundraising or capital structure changes, it fits best under Capital/Financing Update (CAP) as it relates to progress in product development which can impact company valuation and financing considerations. It is not a report publication announcement, earnings release, or regulatory filing. Therefore, the most appropriate classification is CAP with high confidence.
2006-03-12 English
Opens New Research Laboratory Facility at La Trobe Uni. 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Imugene Limited dated 7th March 2006. It discusses the opening of a new research laboratory facility and details about their bird flu vaccine research programs. The content is focused on operational updates and scientific research progress rather than financial results, regulatory filings, or shareholder information. There is no indication of financial statements, audit information, management changes, voting results, or other regulatory filings. The document is a corporate announcement about research and development activities, which fits best under a general regulatory announcement category rather than a specific financial or governance report. Given the nature and length of the document, it is not a report publication announcement or a detailed financial report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2006-03-06 English
Commitments Test Entity - Second Quarter Report 10 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'MARKET UPDATE' and is described as a 'Quarterly report for October - December 2005'. It contains detailed operational and commercial updates, including regulatory approvals, licensing agreements, and product development progress. It also includes a consolidated statement of cash flows for the quarter ended 31 December 2005, with specific financial data such as cash flows related to operating activities, research and development rebates, and net operating cash flows. The presence of substantive financial data and analysis for a period shorter than a full fiscal year (quarterly) indicates this is a comprehensive interim financial report. The document is about 15,000 characters long, which is consistent with a full report rather than a brief announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2006-01-30 English
Granted licence for Poultry Growth Product 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 30 January 2006 regarding Imugene Limited receiving regulatory licenses from the Office of the Gene Technology Regulator (OGTR) and the Australian Pesticides and Veterinary Medicines Authority (APVMA) for a poultry growth product. The content focuses on regulatory approvals and permits for product trials and commercialisation steps. It does not contain financial statements, earnings data, management discussion, or detailed report content. The document length is 3874 characters, which is relatively short and reads as a regulatory announcement rather than a full report. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a certification or officer attestation. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about licensing and permits related to product development and regulatory progress, which does not fit into more specific categories like capital updates, earnings, or management reports.
2006-01-29 English
Trading Halt 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a market release announcing a trading halt for Imugene Limited pending a regulatory approval announcement. It is dated 27 January 2006 and includes a formal request for a voluntary trading halt. The content is brief and does not contain any financial data, report details, or analysis. It is clearly an announcement related to trading status rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2006-01-26 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.